Percutaneous patent foramen ovale closure during live case demonstrations.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
01 04 2019
Historique:
received: 26 01 2018
revised: 24 10 2018
accepted: 14 11 2018
pubmed: 15 12 2018
medline: 19 5 2020
entrez: 15 12 2018
Statut: ppublish

Résumé

Live case demonstrations serve as an educational tool for interventional techniques in cardiology. The aim of this study was to assess the safety and technical success of percutaneous patent foramen ovale (PFO) closure during live case demonstrations. All patients who had undergone percutaneous PFO closure with Amplatzer devices during live case demonstrations at our institution were consecutively included in this retrospective analysis. Procedure related events were compared with summary event rates derived from the eight randomized controlled trials (RCTs) investigating PFO closure, as well as with a propensity matched cohort of patients treated under usual conditions. From April 2004 to June 2015, 142 patients underwent percutaneous PFO closure during live demonstrations, mainly for secondary prevention of cryptogenic cerebrovascular events. The interventions were fluoroscopy guided and successful in all but three cases (2%). Minor adverse events occurred in nine patients (6%). Contrast TEE performed at about 6 months showed complete closure in 84%. No significant differences with regard to technical success and major complications rate were found compared to RCTs, except for an increased rate of minor bleeding observed during live case demonstrations (P for difference < 0.001), mainly attributable to concomitant arterial access for incidental coronary angiography performed in 70% of patients. Except for slightly longer procedure duration, no difference was found compared to a matched population treated under usual conditions. Percutaneous PFO closure can be performed during live case demonstrations with the same high technical success as during routine cases.

Sections du résumé

BACKGROUND
Live case demonstrations serve as an educational tool for interventional techniques in cardiology. The aim of this study was to assess the safety and technical success of percutaneous patent foramen ovale (PFO) closure during live case demonstrations.
METHODS
All patients who had undergone percutaneous PFO closure with Amplatzer devices during live case demonstrations at our institution were consecutively included in this retrospective analysis. Procedure related events were compared with summary event rates derived from the eight randomized controlled trials (RCTs) investigating PFO closure, as well as with a propensity matched cohort of patients treated under usual conditions.
RESULTS
From April 2004 to June 2015, 142 patients underwent percutaneous PFO closure during live demonstrations, mainly for secondary prevention of cryptogenic cerebrovascular events. The interventions were fluoroscopy guided and successful in all but three cases (2%). Minor adverse events occurred in nine patients (6%). Contrast TEE performed at about 6 months showed complete closure in 84%. No significant differences with regard to technical success and major complications rate were found compared to RCTs, except for an increased rate of minor bleeding observed during live case demonstrations (P for difference < 0.001), mainly attributable to concomitant arterial access for incidental coronary angiography performed in 70% of patients. Except for slightly longer procedure duration, no difference was found compared to a matched population treated under usual conditions.
CONCLUSION
Percutaneous PFO closure can be performed during live case demonstrations with the same high technical success as during routine cases.

Identifiants

pubmed: 30548794
doi: 10.1002/ccd.28018
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

982-988

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Fabien Praz (F)

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

George Cm Siontis (GC)

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

Adrian Xhigoli (A)

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

Andreas Wahl (A)

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

Njomeza Susuri (N)

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

Stefan Stortecky (S)

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

Aris Moschovitis (A)

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

Lorenz Räber (L)

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

Thomas Pilgrim (T)

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

Stephan Windecker (S)

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

Bernhard Meier (B)

Department of Cardiology, University Hospital of Bern, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH